Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 12:52 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 68 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Severe Osteoarthritis of the Knee Clear all
Completed Phase 3 Interventional Results available

A Phase 3 Efficacy and Safety Study of Intra-articular CNTX-4975-05 (Capsaicin) vs Placebo in Subjects With OA Knee Pain

NCT03429049
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
CNTX-4975-05, Placebo
Drug
Lead sponsor
Centrexion Therapeutics
Industry
Eligibility
40 Years to 95 Years
Enrollment
332 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
33
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2022 · Synced Oct 9, 2026, 12:52 PM EDT
Completed Phase 2 Interventional Results available

A Study Evaluating the Safety and Efficacy of SM04690 for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis

NCT03122860
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
SM04690, Placebo, Sham
Drug · Other
Lead sponsor
Biosplice Therapeutics, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
74
States / cities
Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 68 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2021 · Synced Oct 9, 2026, 12:52 PM EDT
Completed Phase 2 Interventional

Lyophilized and Micronized Particulate Human Amniotic and Umbilical Cord (TTAX03) for KL Grade 3-4 Knee OA

NCT05079035
View directory record Official record
Conditions
Knee Osteoarthritis, Knee Pain Chronic, Knee Arthritis
Interventions
TTAX03, Saline
Biological
Lead sponsor
BioTissue Holdings, Inc
Industry
Eligibility
35 Years to 85 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
10
States / cities
Birmingham, Alabama • Tucson, Arizona • La Mesa, California + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2025 · Synced Oct 9, 2026, 12:52 PM EDT
Completed Phase 1 Interventional

A Study of Single and Repeat Dose Administration of UBX0101 in Patients With Osteoarthritis of the Knee

NCT04229225
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
UBX0101, Placebo
Drug · Other
Lead sponsor
Unity Biotechnology, Inc.
Industry
Eligibility
40 Years to 85 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
7
States / cities
The Villages, Florida • Marietta, Georgia • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Oct 9, 2026, 12:52 PM EDT
Completed Phase 3 Interventional Results available

Trial to See if Topical Pennsaid for Knee Pain Affects Coagulation Values in Patients Who Are Also Taking Anticoagulants

NCT01511939
View directory record Official record
Conditions
Osteoarthritis of the Knee, Coagulopathy
Interventions
Pennsaid
Drug
Lead sponsor
Nathan Wei, MD, FACP, FACR:
Other
Eligibility
55 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Frederick, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 26, 2014 · Synced Oct 9, 2026, 12:52 PM EDT
Completed Not applicable Interventional

Effectiveness and Safety of Embosphere Microspheres for Embolization of the Geniculate Artery for the Treatment of Pain With Known Moderate to Severe Knee Osteoarthritis

NCT05112926
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Embosphere Microspheres
Device
Lead sponsor
University of Miami
Other
Eligibility
40 Years to 80 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 9, 2026, 12:52 PM EDT
Completed Phase 1 Interventional

Study of Resiniferatoxin for Knee Pain in Moderate to Severe Osteoarthritis

NCT03542838
View directory record Official record
Conditions
Osteoarthritis, Knee, Pain, Knee
Interventions
Resiniferatoxin, Saline
Drug
Lead sponsor
Sorrento Therapeutics, Inc.
Industry
Eligibility
35 Years to 85 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
4
States / cities
Los Angeles, California • Miami, Florida • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2021 · Synced Oct 9, 2026, 12:52 PM EDT
Withdrawn Phase 4 Interventional

An Open-label Evaluation of Tapentadol Extended Release (ER) in Participants With Moderate to Severe Chronic Pain After Conversion From Hydrocodone, Oxycodone Controlled Release (CR), and/or Morphine Sustained Release (SR)

NCT01631513
View directory record Official record
Conditions
Pain, Chronic Back Pain, Chronic Low Back Pain, Osteoarthritis Pain In The Hip or Knee
Interventions
Nucynta ER
Drug
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years to 74 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
7
States / cities
Jacksonville, Florida • Prairie Village, Kansas • Mandeville, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2018 · Synced Oct 9, 2026, 12:52 PM EDT
Completed Phase 2 Interventional

Safety and Tolerability of 4975 in the Treatment of Moderate to Severe Knee Pain Due to Osteoarthritis (OA)

NCT00667654
View directory record Official record
Conditions
Osteoarthritis of the Knee
Interventions
CNTX-4975
Drug
Lead sponsor
Centrexion Therapeutics
Industry
Eligibility
40 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 6, 2016 · Synced Oct 9, 2026, 12:52 PM EDT
Terminated Phase 2 Interventional Results available

MRI Study to Evaluate the Safety and Efficacy of SM04690 for Knee Osteoarthritis

NCT03706521
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
lorecivivint
Drug
Lead sponsor
Biosplice Therapeutics, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 9, 2026, 12:52 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Buprenorphine Transdermal System in Subjects With Moderate to Severe Osteoarthritis of Hip or Knee

NCT00313846
View directory record Official record
Conditions
Osteoarthritis
Interventions
Buprenorphine transdermal patch, Placebo
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
40 Years to 75 Years
Enrollment
529 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
44
States / cities
Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2012 · Synced Oct 9, 2026, 12:52 PM EDT
Completed Phase 2 Interventional Results available

A Study Evaluating the Safety, Tolerability, and Efficacy of SM04690 Injected in the Target Knee Joint of Moderately to Severely Symptomatic Osteoarthritis Subjects

NCT02536833
View directory record Official record
Conditions
Osteoarthritis
Interventions
SM04690, Placebo
Drug
Lead sponsor
Biosplice Therapeutics, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
36
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 32 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2021 · Synced Oct 9, 2026, 12:52 PM EDT
Completed Not applicable Interventional

An Exploratory Clinical Study to Investigate Biomarkers of Senescence in Patients With Osteoarthritis of the Knee

NCT03100799
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
Arthroscopy, Arthrocentesis, MRI
Procedure · Diagnostic Test
Lead sponsor
Unity Biotechnology, Inc.
Industry
Eligibility
35 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Frederick, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 1, 2017 · Synced Oct 9, 2026, 12:52 PM EDT
Completed Not applicable Interventional

A Biologic Joint Replacement Strategy for Knee Trauma and Post-Traumatic Osteoarthritis

NCT03719417
View directory record Official record
Conditions
Knee Osteoarthritis, Post-traumatic Osteoarthritis
Interventions
Unicompartmental Biologic Arthroplasty, Extensive Biologic Arthroplasty
Procedure
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 2, 2022 · Synced Oct 9, 2026, 12:52 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Safety and Efficacy of a Single Dose of UBX0101 in Patients With Osteoarthritis of the Knee

NCT04129944
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
UBX0101, Placebo
Drug · Other
Lead sponsor
Unity Biotechnology, Inc.
Industry
Eligibility
40 Years to 85 Years
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
20
States / cities
Birmingham, Alabama • Mobile, Alabama • Tempe, Arizona + 17 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2021 · Synced Oct 9, 2026, 12:52 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Study To Assess The Efficacy, Tolerability, And Safety OF NKTR-181 In Subjects With Chronic OA Knee Pain

NCT01619839
View directory record Official record
Conditions
Osteoarthritis of the Knee
Interventions
NKTR-181, Placebo
Drug
Lead sponsor
Nektar Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
34
States / cities
Mobile, Alabama • Tucson, Arizona • Garden Grove, California + 29 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2021 · Synced Oct 9, 2026, 12:52 PM EDT
Terminated No phase listed Observational

Long-Term Follow-Up Study of Patients With Osteoarthritis of the Knee Treated With UBX0101 or Placebo

NCT04349956
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
UBX0101 or placebo
Drug
Lead sponsor
Unity Biotechnology, Inc.
Industry
Eligibility
40 Years to 85 Years
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
17
States / cities
Mobile, Alabama • Tempe, Arizona • Tucson, Arizona + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2020 · Synced Oct 9, 2026, 12:52 PM EDT
Completed Phase 3 Interventional Results available

An Open-label, 8-week Safety, Efficacy, and Assessment of Cooling Methods for Administration of CNTX-4975-05 for Knee OA

NCT03661996
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
CNTX-4975-05, Lidocaine without epinephrine, ElastoGel, Breg Ice Water Pump
Drug · Device
Lead sponsor
Centrexion Therapeutics
Industry
Eligibility
40 Years to 95 Years
Enrollment
854 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
28
States / cities
Birmingham, Alabama • Peoria, Arizona • Tucson, Arizona + 24 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2022 · Synced Oct 9, 2026, 12:52 PM EDT
Completed Phase 3 Interventional Results available

A Study of Embeda (Kadian NT, ALO-01) in Subjects With Pain Due to Osteoarthritis of the Hip or Knee

NCT00420992
View directory record Official record
Conditions
Osteoarthritis, Chronic Pain
Interventions
ALO-01 (Morphine Sulfate Plus Naltrexone Hydrochloride Extended Release), Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
21 Years and older
Enrollment
547 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
81
States / cities
Birmingham, Alabama • Mobile, Alabama • Peoria, Arizona + 69 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2013 · Synced Oct 9, 2026, 12:52 PM EDT
Withdrawn Not applicable Interventional

Genicular Artery Embolization (GAE) for Osteoarthritic Knee Pain

NCT04472091
View directory record Official record
Conditions
Knee Osteoarthritis, Knee Pain Chronic, Knee Pain Swelling, Knee Arthritis, Arterial Occlusion
Interventions
Genicular artery embolization (GAE)
Device
Lead sponsor
Andrew Picel
Other
Eligibility
40 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Feb 24, 2025 · Synced Oct 9, 2026, 12:52 PM EDT
Completed No phase listed Observational Results available

A Biologic Joint Replacement Strategy to Treat Patients With Severe Knee Trauma and Post-Traumatic Knee Osteoarthritis

NCT03257371
View directory record Official record
Conditions
Post-traumatic Osteoarthritis
Interventions
Not listed
Lead sponsor
James Stannard
Other
Eligibility
18 Years to 50 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 26, 2021 · Synced Oct 9, 2026, 12:52 PM EDT
Completed Phase 1 Interventional

Phase 1, Dose Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SM04690 in Moderate to Severe Knee Osteoarthritis (OA)

NCT02095548
View directory record Official record
Conditions
Moderate to Severe Osteoarthritis
Interventions
SM04690, 0.03mg/2mL, SM04690, 0.07mg/2mL, SM04690, 0.23mg/2mL, Placebo
Drug
Lead sponsor
Biosplice Therapeutics, Inc.
Industry
Eligibility
50 Years to 75 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
7
States / cities
Tucson, Arizona • El Cajon, California • Walnut Creek, California + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2015 · Synced Oct 9, 2026, 12:52 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of a Subcutaneous Tanezumab Titration Dosing Regimen in Subjects With Moderate to Severe Osteoarthritis of the Hip or Knee

NCT02697773
View directory record Official record
Conditions
Osteoarthritis, Knee, Osteoarthritis, Hip
Interventions
Placebo, Tanezumab 2.5 mg, Tanezumab 2.5mg/5mg
Other · Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
698 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
68
States / cities
Birmingham, Alabama • Phoenix, Arizona • Surprise, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated May 3, 2021 · Synced Oct 9, 2026, 12:52 PM EDT
Terminated Phase 2 Interventional

A Safety and Tolerability Study of JNJ-42160443 in Patients With Moderate to Severe, Chronic Knee Pain From Osteoarthritis

NCT01094262
View directory record Official record
Conditions
Osteoarthritis, Osteoarthritis, Knee, Pain, Arthralgia, Joint Pain
Interventions
Oxycodone CR (standard pain medication), JNJ-42160443, Placebo
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
40 Years to 80 Years
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
36
States / cities
Tucson, Arizona • Carmichael, California • Pismo Beach, California + 33 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2020 · Synced Oct 9, 2026, 12:52 PM EDT